Abstract

Introduction: Pertussis is a vaccine preventable disease. Recently the is a rise in number of cases of Pertussis in developed countries. Under Universal Immunisation Programme in India two doses of TT vaccine are administered. One dose at 5 months of gestation or as soon as detection of pregnancy and the other 4 weeks apart. American College of Obstetricians and Gynecologists recommends a dose of Tdap during pregnancy. CDC also recommends a dose of Tdap vaccine to all pregnant women between 27- 36 weeks of gestation. This study has been conducted to know the level of IgG antibodies against Pertussis toxin in antenatal women since there is a dearth of literature in this aspect. Materials & Methods: Blood samples have been collected from 91 Antenatal women attending outpatient department of Tertiary Care Hospital, Hyderabad after obtaining consent. Serum has been separated and stored at -200C. ELISA has been put up against Pertussis toxin and Serum Anti-Pertussis toxin IgG antibody levels were analysed. Results: A value of >30 IU/ml was accepted as potential protective concentration, 20 -30 IU/ml as borderline &<20 IU/ml as negative. We found that the percentage of protected, borderline and unprotected antenatal women respectively were 16.48%, 9.89% & 73.62% for anti PT. Discussion: Most pregnant women in this study demonstrated low anti PT IgG. This finding suggests that a significant number of women & newborn were susceptible to Pertussis. Conclusion: Our results explained the susceptibility for Pertussis among pregnant women and also newborn born to them & supported the requirement for a Pertussis booster vaccine during pregnancy along with Tetanus and Diphtheria which may provide passive seroprotection in newborns during first months of life decreasing severity of illness and providing seroprotection.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call